Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal-Weight and raises the price target from $20 to $22.